النرويج -
النرويجية -
Statens legemiddelverk
vesicare 5 mg
orifarm as - solifenacinsuksinat - tablett, filmdrasjert - 5 mg
النرويج -
النرويجية -
Statens legemiddelverk
vesicare 10 mg
orifarm as - solifenacinsuksinat - tablett, filmdrasjert - 10 mg
النرويج -
النرويجية -
Statens legemiddelverk
vesicare 10 mg
orifarm as - solifenacinsuksinat - tablett, filmdrasjert - 10 mg
النرويج -
النرويجية -
Statens legemiddelverk
nimotop 0.2 mg/ ml
orifarm as - nimodipin - infusjonsvæske, oppløsning - 0.2 mg/ ml
النرويج -
النرويجية -
Statens legemiddelverk
nimotop 0.2 mg/ ml
orifarm as - nimodipin - infusjonsvæske, oppløsning - 0.2 mg/ ml
الاتحاد الأوروبي -
النرويجية -
EMA (European Medicines Agency)
ontilyv
bial portela & companhia s.a. - opicapone - parkinsonsykdom - anti-parkinson medisiner - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.
الاتحاد الأوروبي -
النرويجية -
EMA (European Medicines Agency)
sorafenib accord
accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastiske midler - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
النرويج -
النرويجية -
Statens legemiddelverk
mezavant 1200 mg
orifarm as - mesalazin - enterodepottablett - 1200 mg
النرويج -
النرويجية -
Statens legemiddelverk
mezavant 1200 mg
orifarm as - mesalazin - enterodepottablett - 1200 mg
النرويج -
النرويجية -
Statens legemiddelverk
mezavant 1200 mg
orifarm as - mesalazin - enterodepottablett - 1200 mg